Inclusion Criteria:

- Histologically documented NSCLC (tumor tissue samples will be provided to look for
assessment of EGFR status with CISH, immunochemistry and mutations) : adenocarcinoma,
squamous cell carcinoma, large cell carcinoma. A cytological documentation of NSCLC
is accepted.

- Stage IV disease or metastatic relapse in not previously irradiated areas of a NSCLC
previously treated with surgery or radiation therapy (with a histologically
documented proof of relapse) or stage III B with documented pleural involvement.

- Measurable disease according to the RECIST criteria.

- Prior radiotherapy authorized except for irradiation concerning measurable disease.

- Age >18 and < 70 years.

- PS < 2.

- Normal hepatic function : serum bilirubin < 1.5 ULN, SGOT (ASAT) and SGPT (ALAT) <
2,5 ULN ; in presence of liver metastases, SGOT and SGPT must be < 5 x ULN.

- Creatinine clearance > 60 mL/min.

- Granulocyte count > 1,5 giga/L, platelet count > 100 giga/L.

- Life expectancy > 12 weeks.

- Written (signed) informed consent for use of tumors samples.

- Written (signed) informed consent to participate in the sudy.

Exclusion Criteria:

- Small cell lung cancer, bronchiolo-alveolar carcinoma, neuro-endocrine carcinoma.

- PS > 1.

- Prior chemotherapy other than cisplatin-gemcitabine.

- Prior therapy with EGFR inhibitor (e.g. monoclonal antibody).

- No concomitant therapy with phenytoin, carbamazepine, rifampicine or phenobarbital.

- Concomitant radiotherapy except for localized bone irradiation.

- Symptomatic brain metastases.

- Superior vena cava syndrome.

- Any unstable systemic disease : significant cardiovascular disease including
myocardial infarction within the previous year, active infection, significant hepatic
or renal disease.

- Pre-existing interstitial lung disease.

- Any inflammatory changes of the surface of the eyes.

- Psychiatric disease with inability to understand the study or to comply with
follow-up procedures.

- Grade > or = 2 peripheral neuropathy.

- Any other malignancies within 5 years (except for treated carcinoma in situ of the
cervix or basal cell skin cancer).

- Pregnant or lactating women ; patients with reproductive potential must use effective
contraception.

- Inability to comply with follow-up procedures.